Overview
- The European Medicines Agency issued a positive opinion for Moderna’s mCombriax, the EU’s first dual COVID‑19 and influenza shot for those aged 50 and above.
- Trials involving about 8,000 participants over 50 showed protection comparable to receiving two separate vaccines.
- The vaccine uses mRNA components to target SARS‑CoV‑2 and three influenza strains, combining elements from previously approved shots.
- Reported side effects include pain at the injection site, fatigue, muscle or headache, nausea or fever, typically resolving within two to three days.
- Formal authorization by the European Commission is expected, after which member states will determine national use, with a single dose expected to simplify seasonal vaccination programs.